Clinical Trials Sponsored by Panbela Therapeutics
Total 6506 results
-
Heron TherapeuticsCompleted
-
Sage TherapeuticsCompleted
-
Sage TherapeuticsCompleted
-
Sage TherapeuticsCompletedPostpartum DepressionUnited States
-
Sage TherapeuticsCompletedSuper-Refractory Status EpilepticusUnited States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Serbia, Spain, Sweden, United Kingdom
-
Sage TherapeuticsCompletedPostpartum DepressionUnited States
-
Amicus TherapeuticsCompletedVariant Late-Infantile Neuronal Ceroid LipofuscinosisUnited States
-
Celldex TherapeuticsCompleted
-
Sage TherapeuticsCompleted
-
Halozyme TherapeuticsCompletedDermatitis, Allergic ContactUnited States
-
CytomX TherapeuticsTerminatedSolid Tumor | Unresectable or Metastatic MelanomaKorea, Republic of, United States, Netherlands, Spain, Australia
-
Fate TherapeuticsTerminatedHematologic MalignanciesUnited States
-
Fate TherapeuticsCompletedMelanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid TumorUnited States
-
Fulcrum TherapeuticsCompletedHealthy Adult SubjectsUnited States
-
Blade TherapeuticsCompletedRelative BioavailabilityAustralia
-
Heron TherapeuticsCompleted
-
Halozyme TherapeuticsCompleted
-
TR TherapeuticsCompleted
-
Heron TherapeuticsCompleted
-
Heron TherapeuticsCompletedPostoperative PainUnited States, Belgium
-
Heron TherapeuticsCompleted
-
Causeway TherapeuticsCompletedTennis ElbowUnited Kingdom
-
Corcept TherapeuticsCompleted
-
UNION therapeuticsCompleted
-
Phoenicis TherapeuticsTerminatedEpidermolysis Bullosa Dystrophica, Recessive | Epidermolysis Bullosa Dystrophica, DominantUnited States, Spain, France
-
Allergy TherapeuticsWithdrawnType I HypersensitivityCanada
-
Cadent TherapeuticsCompleted
-
Nektar TherapeuticsCompletedColorectal CancerUnited States, Belgium, Germany, India, Spain, United Kingdom
-
Nektar TherapeuticsTerminatedModerate to Severe Chronic PainUnited States
-
AKARI TherapeuticsCompletedBullous Pemphigoid (BP)Germany, Netherlands
-
Nektar TherapeuticsCompletedMetastatic Breast Cancer | Locally Recurrent Breast CancerUnited States, Spain, Korea, Republic of, Canada, United Kingdom, Germany, France, Netherlands, Belgium, Italy, Russian Federation
-
vTv TherapeuticsTerminatedAlzheimer's DiseaseUnited States, Canada
-
Bioniz TherapeuticsCompletedLGL Leukemia | CTCLUnited States
-
Intrinsic TherapeuticsWithdrawnLumbar Disc Herniation | Anular Tear of Lumbar Disc | Nucleus Pulp Hernia;LumbosacUnited States
-
Allergy TherapeuticsCompleted
-
CytomX TherapeuticsWithdrawnSolid Tumor, AdultUnited States
-
Symbiomix TherapeuticsCompleted
-
Akebia TherapeuticsCompletedAnemia | Dialysis Dependent Chronic Kidney DiseaseJapan
-
Acorda TherapeuticsCompleted
-
Sangamo TherapeuticsCompletedHuman Immunodeficiency Virus (HIV)United States
-
Blade TherapeuticsWithdrawnIdiopathic Pulmonary FibrosisUnited Kingdom
-
Cristal TherapeuticsCompletedCancer | Ovarian CancerNetherlands, Belgium, United Kingdom
-
Amicus TherapeuticsCompletedOpen-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseaseFabry DiseaseUnited States, Austria, United Kingdom, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Egypt, France, Italy, Japan, Spain, Turkey
-
PTC TherapeuticsCompletedDuchenne Muscular Dystrophy | Becker Muscular Dystrophy | DystrophinopathyUnited Kingdom, Canada, Germany, Spain, Sweden, Italy, Australia, Belgium, France, Israel
-
Arthrosi TherapeuticsCompletedHealthy VolunteersAustralia
-
Symbiomix TherapeuticsCompleted
-
United TherapeuticsTerminatedPulmonary Hypertension | Heart Failure With Preserved Ejection FractionUnited States
-
AKARI TherapeuticsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Kazakhstan, Lithuania, Sri Lanka
-
Effector TherapeuticsTerminated
-
Blade TherapeuticsWithdrawn